Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome.

@article{Xue2008AntiVEGFAC,
  title={Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome.},
  author={Yuan Xue and Piotr Religa and Renhai Cao and Anker Jon Hansen and Franco Lucchini and Bernt E V Jones and Yan Wu and Zhenping Zhu and Bronislaw Pytowski and Yuxiang Liang and Weide Zhong and Paolo Vezzoni and Bj{\"o}rn Rozell and Yihai Cao},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2008},
  volume={105 47},
  pages={18513-8}
}
The underlying mechanism by which anti-VEGF agents prolong cancer patient survival is poorly understood. We show that in a mouse tumor model, VEGF systemically impairs functions of multiple organs including those in the hematopoietic and endocrine systems, leading to early death. Anti-VEGF antibody, bevacizumab, and anti-VEGF receptor 2 (VEGFR-2), but not… CONTINUE READING